Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sonrotoclax + dexamethasone + pomalidomide
- Development stage
- Phase 2
- Lead developer
- BeiGene
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination regimen consisting of **sonrotoclax** (BGB-11417), **dexamethasone**, and **pomalidomide**. Sonrotoclax is a potent and selective BCL-2 inhibitor developed to induce apoptosis in malignant cells, particularly in hematologic cancers such as multiple myeloma with t(11;14). Dexamethasone is a synthetic glucocorticoid that exerts immunosuppressive and anti-inflammatory actions. Pomalidomide is an immunomodulatory thalidomide analogue with antineoplastic activity, enhancing T-cell and NK-cell mediated cytotoxicity and targeting the cereblon E3 ubiquitin ligase complex. This experimental combination is studied for relapsed/refractory multiple myeloma, most notably in patients harboring the t(11;14) translocation[1][5][7].
- Brand names
- Pomalyst + sonrotoclax + dexamethasone
- Other names
- Imnovid + dexamethasone + sonrotoclax
02
Targets
BCL-2 (BCL-2 family)CRBN (Cereblon)GR (Glucocorticoid receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on sonrotoclax + dexamethasone + pomalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sonrotoclax + dexamethasone + pomalidomide.